Management of Urothelial Carcinoma: Strategies for Addressing Health Disparities and Promoting Equitable Care

CME: 1.0

Target Audience

This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview

The treatment landscape has evolved significantly for patients with advanced/metastatic urothelial carcinoma. With new evidence and indications for immunotherapy and other targeted therapies, oncology clinicians are challenged to stay abreast of updated practice guidelines, clinical data for new therapies, and strategies for monitoring and mitigating adverse events. In this activity, expert faculty will review novel therapeutic approaches for advanced/metastatic urothelial carcinoma and current evidence to support individualized treatment decisions. Strategies for optimizing patient outcomes and improving multidisciplinary coordinated care for patients with advanced/metastatic urothelial carcinoma will also be discussed.

This enduring activity is a recorded session from Oncology Congress that took place on September 24, 2022.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Evaluate ways to improve multidisciplinary, coordinated care and communication for patients with urothelial carcinoma from rural and underserved settings
  • Integrate current clinical evidence and guideline recommendations into treatment plans with new and emerging targeted therapies for patients with advanced/metastatic urothelial carcinoma
  • Apply best practice strategies to monitor and manage adverse events associated with advanced/metastatic urothelial carcinoma therapy

Post a comment to this article